共 101 条
- [1] Fizazi K(2017)Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer The New England Journal of Medicine 377 352-360
- [2] Tran N(2015)Health-related quality of life in advanced prostate cancer and its treatments: Biochemical failure and metastatic disease populations Clinical Genitourinary Cancer 13 101-112
- [3] Fein L(2016)Role of systemic chemotherapy in metastatic hormone-sensitive prostate cancer Indian Journal of Urology 32 257-261
- [4] Matsubara N(1982)Dimensions of quality of life expressed by men treated for metastatic prostate cancer Social Science & Medicine 45 1299-1309
- [5] Rodriguez-Antolin A(2014)Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy The Journal of Sexual Medicine 11 2571-2580
- [6] Aleeksev B(1972)A utility maximization model for evaluation of health care programs Health Services Research 7 118-133
- [7] Ozguroglu M(2016)Estimating health-state utility for economic models in clinical studies: An ISPOR good research practices task force report Value in Health 19 704-719
- [8] Ye D(2015)Understanding heterogeneity of treatment effect in prostate cancer Current Opinion in Oncology 27 209-216
- [9] Feyerabend S(2015)Chemohormonal therapy in metastatic hormone-sensitive prostate cancer The New England Journal of Medicine 373 737-746
- [10] Protheroe A(2016)Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial The Lancet (London, England) 387 1163-1177